CLINICAL_TRIALS
trial_result
· 2022-01-18
Clinical Trial Update: Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase [Phase 2]
Summary
Phase 2 trial investigating nilotinib as first-line therapy for chronic myeloid leukemia in early chronic phase has been completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: COMPLETED